Articles On Immutep (ASX:IMM)

Clinical trials are being shuttered in increasing numbers in Australia because of the risks posed by COVID-19, but two companies this morning say theirs are moving ahead at speed. Prescient Therapeutics (ASX:PTX) says its phase 1b study of...

Australian company Immutep (ASX:IMM) has announced it has worked with its partner EOC Pharma to review study results and they have confirmed plans to continue advancing Efti in metastatic breast cancer.

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Stockhead’s resident Health and Biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast. In this episode Tim chats with Marc Voigt, executive director and CEO...

The ASX is cracking down on biotech and health companies disclosures around possible coronavirus-linked products. Yesterday TBG Diagnostics (ASX:TDL) was suspended as the ASX looks into why it waited until Wednesday to reveal that a COVID19...

Immutep (ASX:IMM) has announced the US FDA has approved a new Investigational New Drug application for the company's eftilagimod alpha.

Biotechnology company Immutep (ASX: IMM) has received approval from the US Food and Drug Administration for an investigational new drug (IND) application relating to its lead product candidate eftilagimod alpha for the treatment of metastat...

The cat’s not out of the bag yet, but investors are betting that when the feline does escape it will be purring with some very good news indeed. The metaphorical moggy in this case is shares in the immuno-oncological play Immutep (ASX:IMM),...

The Sydney-based biotechnology Immutep (ASX:IMM) company has released new positive data from a trial involving its immunotherapy in combination with MSD's KEYTRUDA (pembrolizumab).

Immutep (ASX:IMM) has announced it will present more mature interim TACTI-002 clinical data at the 34th German Cancer Congress in Berlin later this month.

A rebound in our big banks saw the Aussie stock market recoup half of yesterday’s heavy losses today.  It was a happier day of trading around the globe as Wall Street saw a gradual incline. The Dow Jones gained just over half a per cent...

Shares in cancer treatment specialist Immutep (IMM) are trading strong today on the back of a healthy quarterly report The report focussed largely on the company’s AIPAC clinical trial for treating breast cancer Important data from the tri...

The health sector was the most successful sector on the ASX in 2019. Various small caps made several breakthroughs including with nerve damage and macular degeneration. While cancer remains one fish that has yet to be fried there are small...

Here’s our fortnightly wrap of all the news driving ASX health stocks. Of the ASX’s 136-odd small cap health stocks, 47 saw their share prices fall, 67 improved and 22 were flat. >> Scroll down for a table showing the performance of s...

Biotech company Immutep (IMM) has expanded part C of its TACTI-002 and AIPAC studies due to positive data Part C has been expanded to include an extra 19 patients with non-small cell lung cancer The company also remains on track to repor...

Biotech company Immutep (ASX: IMM) intends to expand ongoing development of its lead drug candidate eftilagimod alpha, otherwise known as “efti”, after welcoming positive clinical data from its TACTI-002 and AIPAC studies. The company said...

The new-look ServTech is pushing its virtual reality technology into dentistry training, being paid $500,000 by a new client for VR dental software. The company changed its name to Vection (ASX:VR1) after buying a European software developm...

Whether a day trader or a long-term investor, we often examine research released by industry experts, brokers and analysts with a view to uncovering the next big thing. The more complex the sector, the more we are likely to rely on informat...

Shares in cancer-fighting biotech Immutep (ASX:IMM) have risen to eight-month highs today, on the back of positive interim data from its phase II clinical trial in patients with non-small cell lung cancer (NSCLC). Immutep is testing whether...

There are no shortage of small cap health and biotech companies listed on the ASX — around 140 or so — but less than 25 are anywhere close to their ultimate dream of bringing a drug successfully to market, a Stockhead analysis has found. Ta...

Dual Listing: When a stock gets listed on two or more stock exchanges, we say that the stock has a dual listing. Why companies go for dual listing? The biggest advantage of dual listing is that the companies get to address a large group of...

Small cap stocks are the stocks of those enterprises that have a low market capitalisation. Estimated market capitalisation of small cap companies is between $300 million and $2 billion. Small cap stocks have several advantages such as the...

Immutep (ASX:IMM) has announced "mature positive efficacy" data from its TACTI-mel Phase 1 clinical study combining its lead product candidate, eftilagimod alpha, with MSD's KEYTRUDA (pembrolizumab) in metastatic melanoma.

Biotech company Immutep (ASX:IMM) just got some positive results in a Phase I clinical trial for its cancer-fighting treatment. Phase I trials are used to test safety of a given drug, before Phase II trials which measure effectiveness. Immu...

Biotechnology company Immutep (ASX: IMM) has reported “mature positive efficacy data” from a Phase I clinical study combining lead drug candidate eftilagimod alpha with Keytruda in the treatment of metastatic melanoma. The TACTI-mel (Two AC...

Sydney-based biotechnology company Immutep (ASX: IMM) has reported a successful rollout to Part A of its TACTI-002 Phase II clinical trial for patients with previously-untreated, inoperable or metastatic non-small cell lung cancer. The comp...

Shares in Bionomics (ASX:BNO) have flown to their highest point since May as it looks redo the failed post traumatic stress disorder trial that wiped out 66 per cent of the company’s value last October. Bionomics conducted a pharmacokinetic...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Immutep (ASX:IMM) has announced that the requisite number of predefined patient responses has been exceeded in cohort 1 of Part A of the TACTI-002 Phase 2 clinical trial based on an interim analysis.

GSK has paid Australian immunotherapy company Immutep (ASX:IMM) a $7.4 million milestone payment after the first patient was dosed in the phase 2 study of GSK2831781 in ulcerative colitis.

Sydney biotech company Immutep is receiving a $7.4 million milestone payment from GSK as it begins a new trial of its drug to treat ulcerative colitis.

Cancer-fighting biotech Immutep (ASX:IMM) has risen off 10-year-long lows after flagging a payment of $7.4m from British pharma giant GSK. Immutep shares got a 14 per cent boost to 2.5c, after closing at 2.2c on Friday. The share price has...

On Stockhead today, the disconnect between federal and state governments on coal, private equity deals are rising and an ‘avalanche’ is laying waste to lithium prices. But first, here’s what you need to know.   The day ahead Data Today the...

Shares in Immuron took a 17 per cent hit this morning after the company revealed its IMM-124E drug did not work in a trial with patients suffering from severe alcoholic hepatitis. Immuron (ASX:IMM), which is developing oral drugs for gut di...

Short & Caught is Stockhead’s fortnightly recap of which ASX small cap stocks are heavily shorted. Stocks that are shorted have investors betting that they fall. Shorting works by “selling” stocks you do not actually own in the hope of...

In this week’s recap of substantial holders, Australian Super became an substantial holder in Gage Roads Brewing (ASX: GRB), a prominent Sydney property magnate bought 16 per cent of Collaborate Corporation, and we look at a number of purch...

The benchmark index S&P/ASX 200 is trading at 6,665.7 on 10 July 2019 (AEST 01:58 PM), up 0.45%, while the S&P/ASX 200 Health Care Index is up 0.4% to 34,275.1. Let us discuss three healthcare stocks listed on ASX, along with their...

A company may require more funds over and above its retained earnings in order to expand its existing operations, develop new businesses, protect market share or buy another company. The requirement of the company can be fulfilled by either...

ASX-listed biotech Immutep has raised about $10 million in an equity deal through Bell Potter Securities. 

Australia is home to some of the top physicians as well as healthcare professionals. For more than 30 years, various companies across the globe have depended on the clinical trial in Australia and its capability to deliver timely results wi...

Immutep (ASX:IMM) has completed patient enrolment of the Phase 2b Active Immunotherapy PAClitaxel clinical trial in HER2-negative/ Hormone Receptor-positive (HR+) metastatic breast cancer.

The below-mentioned health care stocks have come up with significant updates today. Let’s take a quick look at these stocks. MGC Pharmaceuticals Ltd (ASX: MXC) The European based biopharma company, MGC Pharmaceuticals Ltd (ASX: MXC) has si...

The Australian Healthcare System is amongst the most inclusive in the world, and it offers a wide range of services right from catering to general and preventative health and treating more complex conditions in patients. The healthcare syst...

Sydney-based Immutep (ASX:IMM) has announced that the first patient in the INSIGHT-004 phase 1 clinical trial has been enrolled in Germany and has received the first dose of treatment.

06 Jun 2019 - Biotech company Immutep (ASX:IMM) reports that the first patient in the INSIGHT-004 Phase I clinical trial has received the first dose of treatment in Germany.